Dr. Dipenkumar Modi, M.D.
Claim this profileKarmanos Cancer Institute
Expert in Lymphoma
Studies Diffuse Large B-Cell Lymphoma
22 reported clinical trials
48 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
HLA-A negative
2Diffuse Large B-Cell Lymphoma
Stage IV
Stage III
CD20 positive
Affiliated Hospitals
Clinical Trials Dipenkumar Modi, M.D. is currently running
Epcoritamab + GDP
for Non-Hodgkin's Lymphoma
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) between Day 8 through Day 10 of each cycle of combination therapy. Patients will then undergo radiology imaging for disease assessment. Patients may proceed to SCT(autologous or allogeneic) or CAR T-cell therapy or epcoritamab monotherapy upon completion of Cycle 3 per investigator discretion. The rationale for subjects not proceeding to autoSCT or CAR T-cell therapy will be captured in the eCRFs. Patients who do not undergo SCT or CAR T-cell therapy may have the option to receive study treatment with epcoritamab monotherapy following completion of Cycle 3. Epcoritamab monotherapy will be offered to selected subjects who become ineligible to undergo SCT or CAR T-cell therapy (such as social situation, change in subject decision). The decision to offer epcoritamab monotherapy will be per investigator's discretion. However, subjects must have demonstrated a response to the combination therapy (partial remission or complete remission) per disease assessment scans prior to offering epcoritamab monotherapy. Epcoritamab monotherapy should begin 2 weeks following Cycle 3 Day 15. Monotherapy will consist of epcoritamab 48 mg administered subcutaneously on Days 1 and 15 of each 28 day cycle for Cycle 4 to Cycle 9 or until unacceptable toxicity, or disease progression per the Lugano Criteria.
Recruiting1 award Phase 2
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
More about Dipenkumar Modi, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Dipenkumar Modi, M.D. has experience with
- Rituximab
- Cyclophosphamide
- Nivolumab
- Brentuximab Vedotin
- Doxorubicin Hydrochloride
- Dacarbazine
Breakdown of trials Dipenkumar Modi, M.D. has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Dipenkumar Modi, M.D. specialize in?
Is Dipenkumar Modi, M.D. currently recruiting for clinical trials?
Are there any treatments that Dipenkumar Modi, M.D. has studied deeply?
What is the best way to schedule an appointment with Dipenkumar Modi, M.D.?
What is the office address of Dipenkumar Modi, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.